Structural and functional computational analysis of nicotine analogs as potential neuroprotective compounds in Parkinson disease

As the mechanism of interaction between nicotinic receptors with nicotine analogs is not yet fully understood, information at molecular level obtained from computational calculations is needed. In this sense, this work is a computational study of eight nicotine analogs, all with pyrrolidine ring modifications over a nicotine-based backbone optimized with B3LYP-D3/aug-cc-pVDZ. A molecular characterization was performed focusing on geometrical parameters such as pseudo-rotation angles, atomic charges, HOMO and LUMO orbitals, reactivity indexes and intermolecular interactions. Three analogs, A2 (3-(1,3-dimethyl-4,5-dihydro-1h-pirazole-5-yl) pyridine), A3 (3-(3-methyl-4,5-dihydro-1H-pyrazol-5-yl)-pyridine) and A8 (5-methyl-3-(pyridine-3-yl)-4,5-dihydroisoxazole), were filtered suggesting putative neuroprotective activity taking into account different reactivity values, such as their lowest hardness: 2.37 eV (A8), 2.43 eV (A2) and 2.56 eV (A3), compared to the highest hardness value found: 2.71 eV for A5 (3-((2S,4R)-4-(fluoromethyl)-1-methylpyrrolidine-2-il) pyridine), similar to the value of nicotine (2.70 eV). Additionally, molecular docking of all 8 nicotine analogs with the α 7 nicotinic acetylcholine receptor (α 7 nAChR) was performed. High values of interaction between the receptor and the three nicotine analogs were obtained: A3 (-7.1 kcal/mol), A2 (-6.9 kcal/mol) and A8 (-6.8 kcal/mol); whereas the affinity energy of nicotine was -6.4 kcal/mol. Leu116 and Trp145 are key residues in the binding site of α 7 nAChR interacting with nicotine analogs. Therefore, based upon these results, possible application of these nicotine analogs as neuroprotective compounds and potential implication at the design of novel Parkinson's treatments is evidenced.

[1]  D. Donnelly-roberts,et al.  Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. , 1996, Journal of medicinal chemistry.

[2]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[3]  Marcus D. Hanwell,et al.  Avogadro: an advanced semantic chemical editor, visualization, and analysis platform , 2012, Journal of Cheminformatics.

[4]  M. Thun,et al.  Temporal relationship between cigarette smoking and risk of Parkinson disease , 2007, Neurology.

[5]  M. Quik.  Smoking, nicotine and Parkinson's disease , 2004, Trends in Neurosciences.

[6]  M. Quik,et al.  Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease. , 2015, Biochemical pharmacology.

[7]  F. Dajas,et al.  Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra 1 1 Published on the World Wide Web on 1 December 2000. , 2001, Brain Research.

[8]  B. Warżajtis,et al.  Chalcogen analogues of nicotine lactam studied by NMR, FTIR, DFT and X-ray methods. , 2014, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[9]  Hui-Xin Wang,et al.  Smoking and Parkinson’s and Alzheimer’s disease: review of the epidemiological studies , 2000, Behavioural Brain Research.

[10]  Y. Nakagawa,et al.  Changes in mRNA Expression of Nicotinic Acetylcholine Receptor Subunits during Embryonic Development of Mouse Masseter Muscle , 2002, Zoological science.

[11]  Stefan Grimme,et al.  Effect of the damping function in dispersion corrected density functional theory , 2011, J. Comput. Chem..

[12]  T. Koopmans,et al.  Über die Zuordnung von Wellenfunktionen und Eigenwerten zu den Einzelnen Elektronen Eines Atoms , 1934 .

[13]  R. Mailman,et al.  Smoking duration, intensity, and risk of Parkinson disease , 2010, Neurology.

[14]  M. Quik,et al.  Nicotine as a potential neuroprotective agent for Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[15]  J. Hardy,et al.  Parkinson's disease: A broken nosology , 2005, Movement disorders : official journal of the Movement Disorder Society.

[16]  Edward D Levin,et al.  Cognitive effects of nicotine , 2001, Biological Psychiatry.

[17]  G. Barreto,et al.  Targeting the Nicotinic Acetylcholine Receptors (nAChRs) in Astrocytes as a Potential Therapeutic Target in Parkinson's Disease. , 2016, Current pharmaceutical design.

[18]  J. A. Dani,et al.  Overview of nicotinic receptors and their roles in the central nervous system , 2001, Biological Psychiatry.

[19]  S. Limborska,et al.  Molecular mechanisms of pathogenesis of Parkinson's disease. , 2010, International review of cell and molecular biology.

[20]  P. Geerlings,et al.  Conceptual density functional theory. , 2003, Chemical reviews.

[21]  L. Dwoskin,et al.  Identification and synthesis of novel alkaloids from the root system of Nicotiana tabacum: affinity for neuronal nicotinic acetylcholine receptors. , 2005, Life sciences.

[22]  G. Lagoumintzis,et al.  Muscle and neuronal nicotinic acetylcholine receptors , 2007 .

[23]  T. Miyatake,et al.  Effects of smoking in patients with early-onset Parkinson's disease , 1993, Journal of the Neurological Sciences.

[24]  L. Mrówczyńska,et al.  Synthesis and haemolytic activity of novel salts made of nicotine alkaloids and bile acids. , 2014, Bioorganic & medicinal chemistry letters.

[25]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[26]  D. Pogocki,et al.  Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders. , 2007, European journal of pharmacology.

[27]  M. Lochner,et al.  The binding orientation of epibatidine at α7 nACh receptors , 2017, Neuropharmacology.

[28]  K. Marder,et al.  Pooled analysis of tobacco use and risk of Parkinson disease. , 2007, Archives of neurology.

[29]  Y. Saeki,et al.  Developmental Changes in the Nicotinic Acetylcholine Receptor in Mouse Tongue Striated Muscle , 2001, Journal of dental research.

[30]  P. Davies,et al.  Alpha7 nicotinic acetylcholine receptor: A link between inflammation and neurodegeneration , 2008, Neuroscience & Biobehavioral Reviews.

[31]  David B. Sattelle,et al.  Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection , 2009, Pharmacological Reviews.

[32]  M. Bencherif,et al.  Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases , 2011, Cellular and Molecular Life Sciences.

[33]  L. Itti,et al.  Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study , 2009, Nuclear medicine communications.

[34]  Effects of nicotine on K+ currents and nicotinic receptors in astrocytes of the hippocampal CA1 region , 2009, Neuropharmacology.

[35]  G. Leo,et al.  Nicotine and neurodegeneration in ageing. , 2002, Toxicology letters.

[36]  P. Adams,et al.  Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist , 2008, Brain Research.

[37]  C. Gotti,et al.  Neuronal nicotinic receptors: from structure to pathology , 2004, Progress in Neurobiology.

[38]  K. Nakashima,et al.  Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells , 2008, Neuroscience Letters.

[39]  Ming Lu,et al.  Downregulation of DEC1 contributes to the neurotoxicity induced by MPP+ by suppressing PI3K/Akt/GSK3β pathway , 2017, CNS neuroscience & therapeutics.

[40]  (E)-Nicotinaldehyde O-Cinnamyloxime, a Nicotine Analog, Attenuates Neuronal Cells Death Against Rotenone-Induced Neurotoxicity , 2018, Molecular Neurobiology.

[41]  M. Quik,et al.  Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys , 2009, Journal of neurochemistry.

[42]  Malgorzata Baranska,et al.  Tobacco alkaloids analyzed by Raman spectroscopy and DFT calculations , 2012 .

[43]  I. Macquin-Mavier,et al.  Chronic high dose transdermal nicotine in Parkinson's disease: an open trial , 2007, European journal of neurology.

[44]  G. Barreto,et al.  Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson’s disease , 2015, Front. Aging Neurosci..

[45]  M. Quik,et al.  Nicotine and nicotinic receptors; relevance to Parkinson's disease. , 2002, Neurotoxicology.

[46]  R. Simone,et al.  Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. , 2007, CNS & neurological disorders drug targets.

[47]  F. Speizer,et al.  Cigarette smoking and the incidence of Parkinson's disease in two prospective studies , 2001, Annals of neurology.

[48]  Lin Chen,et al.  Ligand-binding domain of an α7-nicotinic receptor chimera and its complex with agonist , 2011, Nature Neuroscience.

[49]  T. Sixma,et al.  Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors , 2001, Nature.

[50]  Synthesis and Pharmacological Properties of 5-Alkyl Substituted Nicotine Analogs , 2012 .

[51]  K. Fuxe,et al.  Central nicotinic receptors, neurotrophic factors and neuroprotection , 2000, Behavioural Brain Research.

[52]  K. Fagerström,et al.  Nicotine may relieve symptoms of Parkinson's disease , 1994, Psychopharmacology.

[53]  J P Changeux,et al.  Nicotinic receptors in wonderland. , 2001, Trends in biochemical sciences.